UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities Exchange~~Date ~~Act~~of Report (Date of ~~1934~~earliest event reported): March 17, 2026

Date of Report (Date of earliest event reported): March 2, 2026

Akari Therapeutics, Plc

(Exact ~~Name~~name of Registrant as Specified in Its Charter)

England and Wales	001-36288	98-1034922
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

401 East Jackson Street, Suite 3300

401 East Jackson Street, Suite 3300

Tampa, FL

33602

(Address of Principal Executive Offices)

(Zip Code)

~~Tampa~~Registrant’s Telephone Number, FL ~~33602~~Including Area Code: (929) 274-7510

(~~Address,~~Former ~~including~~Name ~~zip~~or ~~code~~Former Address, ofif ~~Principal~~Changed ~~Executive~~Since ~~Offices~~Last Report)

Registrant’s telephone number, including area code: (929) 274-7510

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading Symbol(s)	Name of each exchange on which registered
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
American Depositary Shares, each representing 2,000 Ordinary Shares	AKTX	The Nasdaq ~~Capital~~Stock Market LLC
Ordinary Shares, par value $0.000000005 per share*	N/A	The Nasdaq Stock Market LLC

* Trading, but only in connection with the American Depositary Shares.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5 3.~~07.~~03 ~~Submission~~Material ofModification ~~Matters~~ to aRights ~~Vote~~ of Security Holders.

On March 217, 2026, ~~the~~Akari ~~Company~~Therapeutics, ~~held~~Plc ~~a general meeting of shareholders of the Company~~ (the “~~Special General Meeting~~Company”). ~~Proxies~~announced ~~were~~that ~~solicited~~it ~~pursuant~~plans to change the ~~definitive~~ratio ~~proxy~~of ~~statement on~~its ~~Schedule~~American ~~14A~~Depositary Shares ~~filed~~(“ADSs”) onevidencing ~~February~~ordinary 2shares, ~~2026.~~par Atvalue ~~the~~0.000000005 ~~close~~per ofshare ~~business~~(“Ordinary onShares”), ~~the~~from ~~record~~one ~~date~~(1) ADS ~~for~~representing ~~the~~two ~~Special~~thousand ~~General Meeting~~(2,000) ~~the~~Ordinary ~~number~~Share ~~of ordinary~~to ~~shares~~one ~~entitled~~(1) toADS ~~vote~~representing ateighty ~~the~~thousand ~~Special~~(80,000) ~~General~~Ordinary ~~Meeting~~Shares ~~was~~(the ~~91,567,009,533~~“Ratio Change”). The ~~number~~Ratio ofChange ~~ordinary~~will ~~shares~~result ~~present~~in ora ~~represented by~~one ~~valid~~for ~~proxy~~forty atreverse ~~the~~split ~~Special~~of ~~General~~issued ~~Meeting~~and ~~established~~outstanding aADSs, ~~quorum~~and ~~for~~it ~~the~~will ~~Special~~have ~~General~~no ~~Meeting~~effect on the Ordinary Shares. The ~~Special~~Ratio ~~General~~Change ~~Meeting~~will ~~duly~~be ~~proceeded in~~effective ~~accordance~~on ~~with~~or ~~the~~about ~~provisions~~March of31, 2026. Although the ~~articles~~market ofprice ~~association~~per ofADS is expected to increase proportionally, the Company, ~~then~~can ingive ~~effect,~~no ~~and~~assurance ~~all~~that ~~matters~~the ~~submitted~~Ratio toChange awill ~~vote~~result of in the Company’s ~~shareholders~~satisfying atand maintaining the ~~Special~~minimum ~~General~~bid ~~Meeting~~price ~~were~~requirement ~~approved~~of Nasdaq.

~~The~~Item ~~voting~~7.01 ~~results~~Regulation ~~below~~FD ~~are final and reported in ordinary shares~~Disclosure.

Ordinary Resolution	For	Against	Abstain	Broker Non-Votes
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Series G Warrants to purchase up to an aggregate of 10,043,774 American Depositary Shares (“ADSs”) and Placement Agent Warrants to purchase up to an aggregate of 504,300 ADSs, and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a registered direct offering and a concurrent private placement that closed on December 17, 2025 and January 20, 2026.	40,370,290,401	307,764,000	8,968,000	–
To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 2,563,713 ADSs and Series G Warrants to purchase up to an aggregate of 2,563,713 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a private placement offering of securities of the Company that closed on December 23, 2025.	40,371,532,401	307,920,000	7,570,000	–
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 2,563,713 ADSs and Series G Warrants to purchase up to an aggregate of 2,563,713 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with a private placement offering of securities of the Company that closed on December 23, 2025.	40,370,370,401	308,000,000	8,652,000	–
To approve, for purposes of complying with Nasdaq Listing Rule 5635(c), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 4,673,963 ADSs and Note Exchange Warrants to purchase up to an aggregate of 4,673,963 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with an exchange of notes that closed on December 17, 2025.	40,371,562,401	308,002,000	7,458,000	–
To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the exercisability of Pre-Funded Warrants to purchase up to an aggregate of 9,502,703 ADSs and Note Exchange Warrants to purchase up to an aggregate of 9,502,703 ADSs and the issuance of the ADSs and ordinary shares underlying such warrants, which were issued in connection with an exchange of notes that closed on December 17, 2025.	40,444,976,401	241,588,000	458,000	–

On March 17, 2026, the Company issued a press release announcing the Ratio Change. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

The information set forth in this Item 7.01 of this Current Report on Form 8-K and in the attached Exhibit 99.1 is deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. The information set forth in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Press release dated March 17, 2026.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	~~Akari Therapeutics, Plc~~	Akari Therapeutics, Plc
Date: March 2, 2026	By:	/s/ Kameel Farag
Date:	March 17, 2026	By:	/s/ Kameel Farag
		Kameel Farag
		Name:	Kameel Farag
		Interim Chief Financial Officer
		Title:	Interim Chief Financial Officer

Filing Compare · Akari Therapeutics Plc